Last €10.05 EUR
Change Today +0.075 / 0.75%
Volume 0.0
B9M On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 1:56 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

btg plc (B9M) Snapshot

Open
€9.72
Previous Close
€9.98
Day High
€10.17
Day Low
€9.72
52 Week High
11/21/14 - €10.17
52 Week Low
11/25/13 - €5.19
Market Cap
3.6B
Average Volume 10 Days
148.5
EPS TTM
--
Shares Outstanding
362.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (B9M)

Related News

No related news articles were found.

btg plc (B9M) Related Businessweek News

No Related Businessweek News Found

btg plc (B9M) Details

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

860 Employees
Last Reported Date: 06/16/14
Founded in 1948

btg plc (B9M) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 657.0K GBP
Compensation as of Fiscal Year 2014.

btg plc (B9M) Key Developments

BTG plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 09:20 AM

BTG plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 09:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

BTG plc Announces Consolidated Earnings Results for the Six Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year of 2014

BTG plc announced consolidated earnings results for the six months ended September 30, 2014. For the six months, the company reported revenue of £191.2 million against £153.0 million a year ago. Operating profit was £42.8 million against £25.0 million a year ago. Profit before tax was £37.6 million against £32.7 million a year ago. Profit for the period was £39.2 million against £23.6 million a year ago. Diluted earnings per share were 10.7 pence against 6.7 pence a year ago. Net cash inflow from operating activities was £43.0 million against £32.5 million a year ago. Purchases of intangible assets were £0.1 million against £0.3 million a year ago. Purchases of property, plant and equipment was £3.6 million against £4.3 million a year ago. The company expects full year of 2014 group revenues to be around the top end of guidance range of £330 million to £345 million, despite adverse foreign exchange impacts. The company expects tax rate of 26% for the year 2014.

BTG Seeks Acquisitions

BTG plc (LSE:BTG) is seeking acquisitions. BTG continue to review external acquisition opportunities both in Interventional Medicine and Specialty Pharmaceuticals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B9M:GR €10.05 EUR +0.075

B9M Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hikma Pharmaceuticals PLC 1,894 GBp -24.00
Impax Laboratories Inc $30.80 USD -0.59
Merit Medical Systems Inc $14.72 USD -0.09
Pfizer Ltd/India 1,679 INR 0.00
RPX Corp $13.25 USD -0.06
View Industry Companies
 

Industry Analysis

B9M

Industry Average

Valuation B9M Industry Range
Price/Earnings 70.4x
Price/Sales 8.4x
Price/Book 4.8x
Price/Cash Flow 42.0x
TEV/Sales 8.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.